↓ Skip to main content

Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment

Overview of attention for article published in BMC Pulmonary Medicine, January 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment
Published in
BMC Pulmonary Medicine, January 2016
DOI 10.1186/s12890-016-0171-y
Pubmed ID
Authors

Anne-Marie Russell, Elena Ripamonti, Carlo Vancheri

Abstract

'Living with IPF and an exploration of Esbriet® - a new treatment' was an exploratory, qualitative, real-world survey of European patients with idiopathic pulmonary fibrosis (IPF) who were receiving treatment with pirfenidone prior to its commercial availability. The aim of the survey was to probe the impact of IPF on patients' quality of life; the role of healthcare professionals and caregivers; the information needs of both patients and their caregivers; and patients' perceptions of pirfenidone as a new treatment option for IPF. Patients from the UK, Germany and Italy, with a diagnosis of IPF (duration >3 months), who were being treated with pirfenidone, were recruited from patient support groups, specialist centres and advocacy groups. Semi-structured, qualitative, in-depth patient interviews of 1-h duration were conducted by an independent researcher. Patients were initially asked about their experiences of living with IPF and then prompted to describe their experiences of taking pirfenidone. Techniques utilised included: the bubble-speech technique; the icon cards projective exercise; and the free association exercise. All interviews were transcribed and analysed by an independent researcher. Forty-five patients (71 % male) were interviewed (mean age 68.5 years; mean time since diagnosis 3.5 years); 87 % of patients reported that diagnosis took >1 year. Patients reported that IPF had a significant physical and emotional impact on their quality of life. The beneficial role played by caregivers and interstitial lung disease specialist nurses (where available) was specifically highlighted. Although most patients were keen for information on IPF, this was often of poor quality, out of date, or in English only. Patients' perceptions of pirfenidone were largely positive and associated with 'hope' but were also influenced by the level of side effects experienced. This survey highlights the impact of IPF on patients' lives, and the need to adequately support both patients and their caregivers. These findings demonstrate the value of seeking patients' perspectives of a chronic disease such as IPF and how this information can be used to guide improvements in care, to best support the needs of patients with this devastating condition.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Unknown 93 99%

Demographic breakdown

Readers by professional status Count As %
Other 16 17%
Student > Master 12 13%
Researcher 12 13%
Student > Bachelor 12 13%
Student > Ph. D. Student 11 12%
Other 14 15%
Unknown 17 18%
Readers by discipline Count As %
Medicine and Dentistry 20 21%
Nursing and Health Professions 14 15%
Psychology 12 13%
Social Sciences 7 7%
Agricultural and Biological Sciences 5 5%
Other 13 14%
Unknown 23 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2016.
All research outputs
#4,709,073
of 15,689,103 outputs
Outputs from BMC Pulmonary Medicine
#329
of 1,283 outputs
Outputs of similar age
#108,213
of 371,887 outputs
Outputs of similar age from BMC Pulmonary Medicine
#41
of 135 outputs
Altmetric has tracked 15,689,103 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,283 research outputs from this source. They receive a mean Attention Score of 4.8. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 371,887 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 135 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.